These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 17167213

  • 1. [Effect of genetic polymorphism of cytochrome P450 3A and transporter gene on pharmacokinetics of tacrolimus, a calcineurin inhibitor].
    Niwa T, Shiraga T, Omura M, Kondo T, Kuroda M, Takagi A.
    Nihon Yakurigaku Zasshi; 2006 Dec; 128(6):395-404. PubMed ID: 17167213
    [No Abstract] [Full Text] [Related]

  • 2. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
    Jun KR, Lee W, Jang MS, Chun S, Song GW, Park KT, Lee SG, Han DJ, Kang C, Cho DY, Kim JQ, Min WK.
    Transplantation; 2009 Apr 27; 87(8):1225-31. PubMed ID: 19384171
    [Abstract] [Full Text] [Related]

  • 3. Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors.
    Utecht KN, Hiles JJ, Kolesar J.
    Am J Health Syst Pharm; 2006 Dec 01; 63(23):2340-8. PubMed ID: 17106006
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.
    Shi Y, Li Y, Tang J, Zhang J, Zou Y, Cai B, Wang L.
    Gene; 2013 Jan 10; 512(2):226-31. PubMed ID: 23107770
    [Abstract] [Full Text] [Related]

  • 6. [Cytochrome P450 3A polymorphism and its importance in cyclosporine and tacrolimus therapy in transplanted patients].
    Duricová J, Grundmann M.
    Ceska Slov Farm; 2007 Oct 10; 56(5):220-4. PubMed ID: 18064802
    [Abstract] [Full Text] [Related]

  • 7. Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects.
    Choi JH, Lee YJ, Jang SB, Lee JE, Kim KH, Park K.
    Br J Clin Pharmacol; 2007 Aug 10; 64(2):185-91. PubMed ID: 17391324
    [Abstract] [Full Text] [Related]

  • 8. [Individualized dosage regimen of immunosuppressive drugs based on pharmacokinetic and pharmacodynamic analysis].
    Fukudo M.
    Yakugaku Zasshi; 2007 Jul 10; 127(7):1081-9. PubMed ID: 17603267
    [Abstract] [Full Text] [Related]

  • 9. PharmGKB summary: cyclosporine and tacrolimus pathways.
    Barbarino JM, Staatz CE, Venkataramanan R, Klein TE, Altman RB.
    Pharmacogenet Genomics; 2013 Oct 10; 23(10):563-85. PubMed ID: 23922006
    [No Abstract] [Full Text] [Related]

  • 10. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation.
    Goto M, Masuda S, Saito H, Uemoto S, Kiuchi T, Tanaka K, Inui K.
    Pharmacogenetics; 2002 Aug 10; 12(6):451-7. PubMed ID: 12172213
    [Abstract] [Full Text] [Related]

  • 11. Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient.
    Masuda S, Uemoto S, Hashida T, Inomata Y, Tanaka K, Inui K.
    Clin Pharmacol Ther; 2000 Jul 10; 68(1):98-103. PubMed ID: 10945321
    [Abstract] [Full Text] [Related]

  • 12. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.
    Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y.
    Clin Pharmacol Ther; 2007 Dec 10; 82(6):711-25. PubMed ID: 17495880
    [Abstract] [Full Text] [Related]

  • 13. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III).
    Yoon SH, Cho JH, Kwon O, Choi JY, Park SH, Kim YL, Yoon YR, Won DI, Kim CD.
    Transplantation; 2013 Mar 27; 95(6):828-34. PubMed ID: 23364483
    [Abstract] [Full Text] [Related]

  • 14. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
    Elens L, Bouamar R, Hesselink DA, Haufroid V, van der Heiden IP, van Gelder T, van Schaik RH.
    Clin Chem; 2011 Nov 27; 57(11):1574-83. PubMed ID: 21903774
    [Abstract] [Full Text] [Related]

  • 15. Tacrolimus nephrotoxicity: beware of the association of diarrhea, drug interaction and pharmacogenetics.
    Leroy S, Isapof A, Fargue S, Fakhoury M, Bensman A, Deschênes G, Jacqz-Aigrain E, Ulinski T.
    Pediatr Nephrol; 2010 May 27; 25(5):965-9. PubMed ID: 20091056
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetic interaction between tacrolimus and amlodipine in a renal transplant child.
    Zhao W, Baudouin V, Fakhoury M, Storme T, Deschênes G, Jacqz-Aigrain E.
    Transplantation; 2012 Apr 15; 93(7):e29-30. PubMed ID: 22450597
    [No Abstract] [Full Text] [Related]

  • 17. Pharmacogenetic determinant of the drug interaction between tacrolimus and omeprazole.
    Zhao W, Fakhoury M, Maisin A, Baudouin V, Storme T, Deschênes G, Jacqz-Aigrain E.
    Ther Drug Monit; 2012 Dec 15; 34(6):739-41. PubMed ID: 23042259
    [Abstract] [Full Text] [Related]

  • 18. [Therapeutic drug monitoring of immunosuppresants].
    Hashida T, Inui K.
    Rinsho Byori; 2001 Jul 15; 49(7):662-4. PubMed ID: 11519126
    [Abstract] [Full Text] [Related]

  • 19. Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation.
    Gervasini G, Garcia M, Macias RM, Cubero JJ, Caravaca F, Benitez J.
    Transpl Int; 2012 Apr 15; 25(4):471-80. PubMed ID: 22369694
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.